<--- Back to Details
First PageDocument Content
Angiotensin II receptor antagonists / Combination drugs / Amides / Carboxylic acids / Amlodipine / Valsartan / Novartis / Antihypertensive drug / Chemistry / Organic chemistry / Calcium channel blockers
Date: 2015-04-01 03:57:49
Angiotensin II receptor antagonists
Combination drugs
Amides
Carboxylic acids
Amlodipine
Valsartan
Novartis
Antihypertensive drug
Chemistry
Organic chemistry
Calcium channel blockers

Press Release BSE: NSE: LUPIN

Add to Reading List

Source URL: www.lupin.com

Download Document from Source Website

File Size: 116,92 KB

Share Document on Facebook

Similar Documents

EZ-SCREEN® CUP Package Insert-II The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

DocID: 1vnGd - View Document

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

DocID: 1uSqq - View Document

Gilead Sciences / Chemistry / HIV/AIDS / Medicine / Organofluorides / Specialty drugs / Prodrugs / Prevention of HIV/AIDS / AIDS Healthcare Foundation / Tenofovir alafenamide / Tenofovir disoproxil / Fixed-dose combination

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

Chemistry / Organic chemistry / Combination drugs / RTT / Diuretics / Thiazides / Sulfonamides / AstraZeneca / Atenolol/chlorthalidone / Candesartan / Budesonide/formoterol / Hydrochlorothiazide

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

DocID: 1rlq4 - View Document

Clinical medicine / Medicine / Cancer / Antineoplastic drugs / Cancer treatments / Signal transduction / Breast cancer / Macrolides / Eribulin / Halichondrin B / MTOR inhibitors / Eisai

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document